These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2488 related articles for article (PubMed ID: 17083854)
21. Adalimumab for the treatment of psoriasis. Turner D; Picot J; Cooper K; Loveman E Health Technol Assess; 2009 Sep; 13 Suppl 2():49-54. PubMed ID: 19804689 [TBL] [Abstract][Full Text] [Related]
22. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Dupire G; Droitcourt C; Hughes C; Le Cleach L Cochrane Database Syst Rev; 2019 Mar; 3(3):CD011571. PubMed ID: 30835819 [TBL] [Abstract][Full Text] [Related]
23. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455 [TBL] [Abstract][Full Text] [Related]
25. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372 [TBL] [Abstract][Full Text] [Related]
27. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798 [TBL] [Abstract][Full Text] [Related]
28. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA; Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770 [TBL] [Abstract][Full Text] [Related]
29. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R; Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365 [TBL] [Abstract][Full Text] [Related]
30. Systemic treatments for eczema: a network meta-analysis. Sawangjit R; Dilokthornsakul P; Lloyd-Lavery A; Lai NM; Dellavalle R; Chaiyakunapruk N Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013206. PubMed ID: 32927498 [TBL] [Abstract][Full Text] [Related]
31. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Mazzotta A; Esposito M; Costanzo A; Chimenti S Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444 [TBL] [Abstract][Full Text] [Related]
33. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256 [TBL] [Abstract][Full Text] [Related]
34. Initial experience with routine administration of etanercept in psoriasis. de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Reich K; Burden AD; Eaton JN; Hawkins NS Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698 [TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984 [TBL] [Abstract][Full Text] [Related]
38. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. Farhi D Drugs Today (Barc); 2010 Apr; 46(4):259-64. PubMed ID: 20502723 [TBL] [Abstract][Full Text] [Related]
39. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). Papp KA; Barber K; Bissonnette R; Bourcier M; Lynde CW; Poulin Y; Shelton J; Toole J; Vieira A; Poulin-Costello M J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):361-366. PubMed ID: 24980988 [TBL] [Abstract][Full Text] [Related]
40. Etanercept treatment for children and adolescents with plaque psoriasis. Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A; N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]